AIM ImmunoTech Inc. Stockholders Equity

• AIM ImmunoTech Inc. showed a decrease of -640.0% in Stockholders Equity from 2024 to 2025.
• This data is from AIM ImmunoTech Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
• XBRL data for this metric is available from 2012 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: $18.41 million | Q2 2016: $17.49 million | Q3 2016: $16.63 million | Q1 2017: $12.95 million | Q2 2017: $10.33 million | Q3 2017: $10.04 million | Q1 2018: $10.20 million | Q2 2018: $9.10 million | Q3 2018: $6.44 million | Q1 2019: $3.93 million | Q2 2019: $6.55 million | Q1 2020: $35.13 million | Q2 2020: $46.99 million | Q3 2020: $61.11 million | Q1 2021: $70.97 million | Q2 2021: $65.53 million | Q3 2021: $62.05 million | Q1 2022: $53.30 million | Q2 2022: $48.78 million | Q3 2022: $42.70 million | Q1 2023: $34.99 million | Q2 2023: $30.14 million | Q3 2023: $22.60 million | Q1 2024: $4.83 million | Q2 2024: $6.10 million | Q3 2024: $2.91 million | Q4 2024: $6.00 million | Q1 2025: -$3.86 million | Q2 2025: -$6.55 million | Q3 2025: -$6.08 million.
• Over the full 15 years of available data (2012 to 2025), AIM ImmunoTech Inc.'s Stockholders Equity has declined by 121.9%.
• Historical annual values: Fiscal year 2025: -$9.78 million | Fiscal year 2024: -$1.32 million | Fiscal year 2023: $10.23 million | Fiscal year 2022: $38.47 million | Fiscal year 2021: $56.88 million | Fiscal year 2020: $61.29 million | Fiscal year 2019: $13.44 million | Fiscal year 2019: $13.44 million | Fiscal year 2018: $5.58 million | Fiscal year 2017: $8.70 million | Fiscal year 2016: $15.50 million | Fiscal year 2015: $20.37 million | Fiscal year 2014: $25.00 million | Fiscal year 2013: $29.30 million | Fiscal year 2012: $44.70 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026